Skip to main content
OpenTrials
Completed

NCT Number: NCT01317563

Antioxidant Therapy in Lean and Obese Asthmatics

This project will assess the effectiveness of antioxidant supplementation with common vitamins A, C, E and selenium in controlling asthma symptoms among lean and obese asthmatics. This project may improve our ability to treat asthma and our understanding of the link between nutritional antioxidants and asthma.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Asthma & Obesity are both growing public health crises that also may be critically interrelated for many patients. Obesity increases the risk for asthma in both adults and children, and obesity increases the severity of existing asthma. Obesity leads to increased systemic oxidative stress, however little is know about obesity-related oxidative stress within the airway. Since oxidative stress contributes to the pathogenesis of asthma, obesity may influence asthma risk and severity through this mechanism. Asthmatics have low serum antioxidant activity. There is conflicting evidence about whether or not antioxidant supplementation reduces asthma severity. This may be related to asthma's heterogeneous nature. Antioxidant supplementation may be effective in select subgroups that have the greater oxidative stress, such as asthmatics with occupational exposures or obesity. In fact, the evidence supporting antioxidant supplementation in asthma involved subjects with oxidant-related triggers. We hypothesize that obesity-related oxidant stress puts asthmatics at risk for increased airway oxidative stress and greater asthma severity. We hypothesize that supplementation with common antioxidants will significantly reduce airway inflammation and oxidative stress, and lead to improved pulmonary function and daily asthma control. This pilot study is designed as a randomized, double-blinded, placebo-controlled, parallel intervention trial involving lean and obese adolescents and young adults with asthma. After the 2-week run-in period, all subjects will undergo baseline testing (see figure 1). At randomization they will receive either placebo or a multivitamin antioxidant for 42 days. At the end of the 42 day intervention all subjects will undergo final testing. Primary Hypothesis: In young asthmatics, antioxidant supplementation increases plasma and airway antioxidant levels leading to improved lung function and asthma control. Secondary Hypotheses: 1) Obesity-related systemic oxidant stress is associated with increased oxidative stress within the airway. 2) Antioxidant supplementation will lead to greater improvements in asthma control among obese compared to lean (not underweight) asthmatics. 3) Antioxidant supplementation will lead to greater improvements in airway markers of inflammation and oxidative stress among obese compared to lean asthmatics. We will assess asthma control and lung function before and after therapy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age 12-25,
  • physician-diagnosed persistent asthma on daily controller therapy,
  • FEV1% >= 60% predicted,
  • Lung responsiveness (>= 12% BD reversibility or PC20 MCT <= 16mg/ml)

Exclusion criteria

  • taking daily MVI,
  • chronic oral steroid therapy,
  • BMI<20th percentile,
  • smoking history,
  • pregnancy,
  • milk allergy,
  • celiac disease

Treatment and study plan

Vitamins A, E, C & Selenium

Dietary Supplement

daily dose = Vitamin A 10000 IU (beta carotene), Vitamin E 400 IU, Vitamin C 1200mg, and Selenium 300mcg.

Placebo

Dietary Supplement

total daily dose = 1200mg whey protein, 800mg microcrystalline cellulose

Primary outcomes

  1. Change in Asthma Control Questionnaire (Juniper)- (ACQ)

    Time frame: 6 weeks

    ACQ is a 7 component test that includes 6 responses elliciting control of asthma symptoms plus one component based on FEV1 (spirometry). The score ranges from 0-6, with a higher score suggesting greater asthma symptoms.

Secondary outcomes

  1. Change in Asthma Symptom Utility Index

    Time frame: 6 weeks

    Questionnaire assessing patient reported asthma symptoms from the previous 2 weeks. Score ranges from 0 to 1 with a higher score suggesting better asthma control.

  2. change in FEV1

    Time frame: 6 weeks

    Spirometric measure of volume expired in 1 second.

Sponsors and collaborators

Lead sponsor

Nemours Children's Clinic

Other

Collaborators

  • American Lung Association

Registry information

Official study title

Phase 2 Study of Antioxidant Therapy in Lean and Obese Asthmatics

Acronym: ALOA

Important dates

Study start
2008
Primary completion
2012
Study completion
2016
First posted
Mar 17, 2011
Registry last updated
Mar 22, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.